Showing 261 - 267 results of 267 for search '"Hematology"', query time: 0.05s Refine Results
  1. 261

    Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries by Anas Hamad, Shereen Elazzazy, Ruba Y. Taha, Hani Osman, Sana Alblooshi, Islam Elkonaissi, Mustaqeem A. Siddiqui, Khalil Al-Farsi, Mohammed Al Lamki, Sali Emara, Gihan H. Elsisi

    Published 2024-07-01
    “…**Background:** The second most common hematologic cancer worldwide is multiple myeloma (MM), with incidence and mortality rates that have more than doubled over the past 30 years. …”
    Get full text
    Article
  2. 262

    The Effects of Adverse Events and Associated Costs on Value-Based Care for Metastatic Pancreatic Ductal Adenocarcinoma by Prachi Bhatt, Jared Hirsch, Paul Cockrum, George Kim, Gabriela Dieguez

    Published 2024-12-01
    “…The development of any studied hematologic AE was associated with a mean excess cost of $5993 per administration, while the development of any studied nonhematological AE was associated with a mean per-administration excess cost of $3665. …”
    Get full text
    Article
  3. 263

    Association between Loa loa microfilaremia and anatomical hyposplenia in a rural area of the Republic of Congo: a population-based cross-sectional study by Charlotte Boullé, Elodie Lebredonchel, Jérémy T. Campillo, Valentin Dupasquier, Marlhand C. Hemilembolo, Sébastien D. S. Pion, Jean Claude Djontu, Ludovic Rancé, Philippe Souteyrand, François Missamou, Michel Boussinesq, Francine Ntoumi, Cédric B. Chesnais

    Published 2025-02-01
    “…Blood samples were analyzed for L. loa MFD, Plasmodium-PCR, Anti-Plasmodium falciparum-IgG, total IgM, sickle-cell disease status, and hematological abnormalities. Linear and logistic regressions were used to assess these associations. …”
    Get full text
    Article
  4. 264
  5. 265

    Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysis by Roberto Buonaiuto, Aldo Caltavituro, Margherita Tafuro, Alessandra Longobardi, Giuliana Pavone, Pierluigi De Santis, Roberta Caputo, Carmine De Angelis, Lucia Del Mastro, Fabio Puglisi, Mario Giuliano, Grazia Arpino, Martina Pagliuca, Michelino De Laurentiis

    Published 2025-02-01
    “…Interestingly, a numerically higher rate of treatment-related hematological toxicity was observed in Asian patients, although no significant interethnic difference was found in the relative risk of these events. …”
    Get full text
    Article
  6. 266

    Early Postoperative Safety of Total Hip Arthroplasty in Systemic Lupus Erythematosus Patients by YANG Xingdong, YU Muyang, XU Yiming, ZHU Wei, HU Mingwei, WENG Xisheng, FENG Bin

    Published 2025-01-01
    “…After propensity score matching, 163 cases from SLE and control groups were included for analysis. (1) Regarding medical complications, compared with control group, SLE group showed significant differences in osteoporosis, respiratory system disorders, gastrointestinal diseases, urinary system disorders, hematologic abnormalities, and secondary or concomitant rheumatic diseases (all P < 0.05). (2) In terms of preoperative laboratory tests, SLE group had lower platelet counts, absolute lymphocyte counts, hemoglobin levels, hematocrit, albumin levels, blood glucose levels, and activated partial thromboplastin times than control group, while C-reactive protein, erythrocyte sedimentation rate, and D-dimer levels were higher (all P < 0.05). (3) Regarding surgical-related indicators, a higher proportion of patients in SLE group had an ASA grade > 2 (15.95% vs. 3.07%, P < 0.001), but intraoperative blood loss was significantly smaller [324.7 (200.0, 500.0) mL vs. 421.8 (200.0, 500.0) mL, P=0.005]. (4) In terms of complications, SLE group exhibited a significantly higher incidence of major complications than control group (8.59% vs. 1.23%, P=0.005), with a relative risk of 1.081 (95% CI: 1.028-1.136). …”
    Get full text
    Article
  7. 267